Why some patients respond poorly to statins and how this might be remedied.
Thompson
G R
GR
Department of Investigative Science, Imperial College School of Medicine, Hammersmith Hospital, London, UK. g.thompson@ic.ac.uk
O'Neill
F
F
Seed
M
M
D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D010349:Patient Compliance / Q000523:psychology; D011725:Pyridines / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; D002784:Cholesterol; D019821:Simvastatin; C086276:cerivastatin